Pershing is hopeful it’ll make an impact in reducing addiction but wants to see the new drug in use before casting a final judgment. “When oxycodone was released, Purdue Pharma told everyone this was ...

Each year, millions of people in America are prescribed a medicine for acute pain.Now, for the first time in over 20 years, ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved JOURNAVX™ (suzetrigine), an oral, non-opioid, highly selective ...

“The FDA approval of suzetrigine (Journavx) opens the door to a new class of oral systemic medications for patients who suffer from acute pain, including pain after surgery,” says Dr. Edward ...

RICHMOND, Va. (WRIC) — The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to severe acute pain in more than 20 years.

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

Novo Nordisk is a great pick to buy with the stock near its 52-week low. Vertex Pharmaceuticals is helping patients and ...

RBC Capital notes that the clinical review documents associated with Sector Perform-rated Vertex Pharmaceuticals (VRTX)’ recent approval of Journavx were posted to FDA’s online repository ...